The potential value of any CGM contract with Nova Biomedical...

The potential value of any CGM contract with Nova Biomedical will be a key component of any strategic alternative for Sensera.

To give some calibration of potential value, Biolinq just raised US$100M in their series B for their CGM patch:

https://www.fiercebiotech.com/medtech/biolinq-amasses-100m-for-its-painless-glucose-sensor-patch

Biolinq still has quite a way to go before commercialisation I think. Looks to be a huge vote of confidence in the CGM market, but also in the tech behind their solution.

Hope any valuation of the Sanvita medical CGM is similarly impressive - I'd be happy with a tenth of that at this stage